Late last year, American chemical conglomerates, Dow and DuPont, arrived at an agreement to merge and form a $130 billion company. This merger will split the new company into three firms focusing on agriculture, material science and specialty products such as biomaterials. However, a new analysis shows that this may not be the “merger of equals”. The core businesses of DuPont, like industrial biosciences, will be under-utilized with this merger and potentially be available for acquisition or spin-out. The industry is looking at large mergers and acquisitions to help add investor value faster and fill in gaps in their offerings, especially in high growth areas.
Read Full News At: http://www.researz.com/dow-dupont-merger-mean-biomaterials-industry